Orchestra BioMed vs Stereotaxis
Orchestra BioMed reported revenue of $34 million in fiscal 2025, about the same as Stereotaxis' $32 million in fiscal 2025. Orchestra BioMed's revenue grew 1169.2% in its latest year, and Stereotaxis' grew 20.3%. Orchestra BioMed had an operating margin of -154.7%, against -68.3% at Stereotaxis. Free cash flow was −$49 million at Orchestra BioMed and −$14 million at Stereotaxis.
Side by side
| Orchestra BioMed | Stereotaxis | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $34M | $32M |
| Revenue growth | 1,169.2% | 20.3% |
| Revenue growth a year, last 5 years | — | 4.0% |
| Gross margin | 99.4% | 52.7% |
| Operating margin | −154.7% | −68.3% |
| Net margin | −157.4% | −66.8% |
| Free cash flow | −$49M | −$14M |
| Free cash flow margin | −147.7% | −42.5% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 29.7% | 6.8% |
| Last close | $7.00 | $1.01 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $259,541, sold $257,682 | bought $135,754, sold $0 |
| Piotroski F-score | 5 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Orchestra BioMedStereotaxis
Operating margin
Percent of revenue
Orchestra BioMedStereotaxis
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Orchestra BioMedStereotaxis
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Orchestra BioMed and Stereotaxis pages.